Exhibit 99.1
Lexaria Bioscience Announces New Research Including Cannabinoid Topical Creams and Nicotine Edibles
Kelowna, British Columbia December 15, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria), a drug delivery platform innovator, announces a new topical skin cream research and development (R&D) program; R&D into nicotine edibles; and updates existing R&D programs.
Topical Skin Formulations for Cannabinoids.
Lexaria
has formulated topical cream products as an extension of its DehydraTECH
technology, for the delivery of cannabinoids into and through the skin which may
prove to have emollient benefits desired by the topical products sector.
Lexarias president, John Docherty M.Sc., has extensive experience as a biotech
company executive and researcher for skin-based delivery of therapeutics.
Multiple Lexaria formulations are scheduled to be laboratory tested for human skin absorption and penetration characteristics during January through March 2018. Testing will be completed at a third-party lab utilizing human skin tissue and the latest in vitro evaluative techniques to measure cannabidiol penetration in the skin. Lexaria expects to optimize formulation and manufacturing processes to develop superior-performing product designs that will potentially be available to licensees during 2018.
Nicotine in Edible Formats.
Lexaria has accelerated
its research focus on nicotine following its recently announced nicotine patent
grant and has been researching edible forms of nicotine which could use the
Companys DehydraTECHTM technology. Formulations have been prepared
and are currently completing quality control testing, prior to in vivo
absorption and tolerability testing in animals.
A third-party Philadelphia based lab has been contracted to
perform the first nicotine edible tests expected in February. In vivo
testing with rats will examine two main outcomes:
1) Gastrointestinal
distress. Without an enabling technology, untreated nicotine causes
gastrointestinal upset and distress making nicotine edibles impractical. The
DehydraTECHTM process will be evaluated for its ability to lessen
gastrointestinal distress thus potentially opening the door to the creation of a
new line of consumer products.
2) Absorption time and efficiency in crossing
the intestinal wall and reaching the bloodstream. Earlier testing of the
DehyrdaTECHTM process using cannabidiol as an active ingredient, proved reduced absorption times and enhanced
intestinal permeability. It is expected that similar outcomes using nicotine may
be experienced.
University of British Columbia (UBC) TurboCBD Study.
As previously announced, the UBC study was initiated with UBC board
evaluation and approvals. However, a recent change in UBC policy has resulted in
all MITACS/UBC studies of this class to be temporarily halted. This change in
policy affects numerous studies at UBC. Lexaria is currently reviewing methods
of modifying the contemplated UBC study and/or alternatives to complete the
planned study objectives at UBC or elsewhere if necessary and will report on
next steps when they are known.
National Research Council.
The National Research
Council and Lexaria have successfully developed model formulations using the
DehydraTECH process and methodology. Following this completed first phase, the
parties now plan to formulate and test DehydraTECH based cannabinoid
formulations in early 2018 to determine the inherent processes that enable the
palatability and absorption benefits DehydraTECH formulations have
demonstrated. This second phase is expected to be performed with cannabinoids
for the first time to provide additional guidance for further study.
Formulation Experimentation.
Lexaria has conducted
various cannabinoid formulation experiments, together with potential
DehydraTECH licensee partners, on chocolates, candies, gummies, mouth-melts,
chocolate bars, protein bars, beverages such as beer, spices, tea, coffee,
supplements and more.
Beverage formulations have produced cannabinoid water-based products including de-alcoholized beer that mask unwanted cannabis flavor and are fast acting. Chocolate formulations were reported as being the fastest acting, most consistent, and best-tasting products in approximately 70% of cases in a recent consumer study. As the recreational markets for cannabis become legal in California and Canada, Lexaria expects increased demand for its superior-performing edible products. Its formulations further allow clients to retain organic food claims as the DehydraTECHTM process does not use any chemicals.
Lexaria will work with new and improved formulations for a variety of food products on a continuous basis throughout 2018 as it broadens its ever growing universe of products under development for potential licensees. This should shorten the technology licensing sales cycle and also assist companies as they collaborate with Lexaria to develop and sell the highest-performing products in their respective sales categories.
About Lexaria
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexarias
technology provides increases in intestinal absorption rates; more rapid
delivery to the bloodstream; and important taste-masking benefits, for orally
administered bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
For regular updates,
connect with Lexaria:
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience
Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance that Lexaria
will successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. Scientific R&D is often
unpredictable and unanticipated results could emerge from any study and have a
material impact. There is no assurance that any planned corporate activity,
scientific study, R&D, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any of Lexarias
postulated uses, benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA). Lexaria
Energy Foods, Ambarii, DehydraTECHTM technology and ViPovaTM
products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.